TrialThe Lancet. Oncology2020

Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial.

Sarah B Goldberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.